Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells
Open Access
- 5 May 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (5) , e0155052
Abstract
To identify the proteins involved the compensatory adaptive response to paclitaxel in ovarian cancer cells and to determine whether inhibition of the compensatory adaptive response increases the efficacy of paclitaxel in decreasing the viability of cancer cells. We used a reverse-phase protein array and western blot analysis to identify the proteins involved in the compensatory mechanism induced by paclitaxel in HeyA8 and SKOV3 ovarian cancer cells. We used a cell viability assay to examine whether inhibition of the proteins involved in the compensatory adaptive response influenced the effects of paclitaxel on cancer cell viability. All experiments were performed in three-dimensional cell cultures. Paclitaxel induced the upregulation of pS6 (S240/S244) and pS6 (S235/S236) in HeyA8 and SKOV3 cells, and pPRAS40 (T246) in HeyA8 cells. BX795 and CCT128930 were chosen as inhibitors of pS6 (S240/S244), pS6 (S235/S236), and pPRAS40 (T246). BX795 and CCT128930 decreased pS6 (S240/S244) and pS6 (S235/S236) expression in HeyA8 and SKOV3 cells. However, pPRAS40 (T246) expression was inhibited only by BX795 and not by CCT128930 in HeyA8 cells. Compared with paclitaxel alone, addition of BX795 or CCT128930 to paclitaxel was more effective in decreasing the viability of HeyA8 and SKOV3 cells. Addition of BX795 or CCT128930 to inhibit pS6 (S240/S244) or pS6 (S235/S236) restricted the compensatory adaptive response to paclitaxel in HeyA8 and SKOV3 cells. These inhibitors increased the efficacy of paclitaxel in reducing cancer cell viability.Keywords
Funding Information
- The Catholic Medical Center Research Foundation in the 2014 program
- The Alumni of Obstetrics and Gynecology, the Catholic University of Korea
This publication has 32 references indexed in Scilit:
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast CancerCancer Cell, 2012
- Dual blockade of phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancerCancer Letters, 2011
- Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapyLeukemia, 2011
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Unraveling the microenvironmental influences on the normal mammary gland and breast cancerSeminars in Cancer Biology, 2008
- Ribosomal S6 Kinase 2 Is a Key Regulator in Tumor Promoter–Induced Cell TransformationCancer Research, 2007
- Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis1Acta Pharmacologica Sinica, 2005
- Neuroprotective Role of a Proline-Rich Akt Substrate in Apoptotic Neuronal Cell Death after Stroke: Relationships with Nerve Growth FactorJournal of Neuroscience, 2004
- Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding PartnerJournal of Biological Chemistry, 2003
- A Novel Amplification at 17q21-23 in Ovarian Cancer Cell Lines Detected by Comparative Genomic HybridizationGynecologic Oncology, 2001